

Olga Graciela CantÃ³-RodrÃ­guez

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8202757/publications.pdf>

Version: 2024-02-01

64
papers

1,104
citations

361388

20
h-index

454934

30
g-index

66
all docs

66
docs citations

66
times ranked

1257
citing authors

#	ARTICLE	IF	CITATIONS
1	Autologous ATG-free hematopoietic stem cell transplantation for refractory autoimmune rheumatic diseases: a Latin American cohort. <i>Clinical Rheumatology</i> , 2022, 41, 869-876.	2.2	5
2	Outpatient haploidentical hematopoietic stem cell transplant using post-transplant cyclophosphamide and incidence of hemorrhagic cystitis. <i>Hematology, Transfusion and Cell Therapy</i> , 2022, 44, 163-168.	0.2	5
3	Outpatient allogeneic hematopoietic stem-cell transplantation: a review. <i>Therapeutic Advances in Hematology</i> , 2022, 13, 204062072210807.	2.5	6
4	Oseltamivir as rescue therapy for persistent, chronic, or refractory immune thrombocytopenia: a case series and review of the literature. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	2.1	3
5	Outpatient Haploidentical Stem Cell Transplantation Using Post-Transplant Cyclophosphamide Is Safe and Feasible. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 259.e1-259.e6.	1.2	11
6	Outpatient transplantation in the COVID-19 era: a single-center Latin American experience. <i>Bone Marrow Transplantation</i> , 2021, 56, 2287-2290.	2.4	3
7	Performance of serum procalcitonin as a biochemical predictor of death in hematology patients with febrile neutropenia. <i>Blood Cells, Molecules, and Diseases</i> , 2021, 90, 102586.	1.4	7
8	Moral Distress: Its Manifestations in Healthy Donors during Peripheral Blood Hematopoietic Stem Cell Harvesting. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 853-858.	1.2	3
9	Cyclosporine A for the Prevention of Ocular Graft versus Host Disease in Allogeneic Hematopoietic Stem Cell Transplant Recipients Is Safe and Feasible. <i>Acta Haematologica</i> , 2020, 143, 425-431.	1.4	6
10	Palliative Care for Patients With Hematologic Malignancies in a Low-Middle Income Country: Prevalence of Symptoms and the Need for Improving Quality of Attention at the End of Life. <i>American Journal of Hospice and Palliative Medicine</i> , 2020, 37, 600-605.	1.4	9
11	Impact of HLA-DPB1 Matching on Clinical Outcomes after Haploidentical-Related Hematopoietic Stem Cell Transplantation. <i>Revista De Investigacion Clinica</i> , 2020, 72, 69-79.	0.4	1
12	Reduced-dose plerixafor as a mobilization strategy in autologous hematopoietic cell transplantation: a proof of concept study. <i>Transfusion</i> , 2019, 59, 3721-3726.	1.6	5
13	Efficacy of three filgrastim-intended copies for hematopoietic stem cell mobilization in healthy adult and pediatric donors in Mexico. <i>Journal of Clinical Apheresis</i> , 2019, 34, 537-544.	1.3	5
14	Eltrombopag, low-dose rituximab, and dexamethasone combination as frontline treatment of newly diagnosed immune thrombocytopenia. <i>British Journal of Haematology</i> , 2019, 184, 288-290.	2.5	21
15	Danazol as First-Line Therapy for Myelodysplastic Syndrome. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, e109-e113.	0.4	16
16	Contributions of a regional approach to document hematologic disease in Mexico: a 10-year experience in an open population. <i>Hematology</i> , 2018, 23, 803-809.	1.5	8
17	Measurements of Catheter, Venous, and Capillary Cyclosporine A Blood Are Comparable and Useful in Pediatric Hematopoietic Stem Cell Transplant Recipients. <i>Acta Haematologica</i> , 2017, 137, 113-116.	1.4	1
18	Real-world outcomes of treatment for acute lymphoblastic leukemia during adolescence in a financially restricted environment: Results at a single center in Latin America. <i>Pediatric Blood and Cancer</i> , 2017, 64, e26396.	1.5	22

#	ARTICLE	IF	CITATIONS
19	High frequency of primary refractory disease and low progression-free survival rate of Hodgkin's lymphoma: a decade of experience in a Latin American center. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 325-330.	0.7	16
20	The prognostic significance of serum XCL1 concentration in patients with acute lymphoblastic leukemia: a pilot study. <i>Annals of Hematology</i> , 2017, 96, 2015-2024.	1.8	5
21	Age Acts as an Adverse Independent Variable for Survival in Acute Lymphoblastic Leukemia: Data From a Cohort in Northeast Mexico. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2017, 17, 590-594.	0.4	8
22	Comparative analysis of iron status and other hematological parameters in preeclampsia. <i>Hematology</i> , 2017, 22, 36-40.	1.5	14
23	Myelodysplasia and acute myeloid leukemia fifteen years after high-dose cyclophosphamide in a child with severe aplastic anemia. <i>Revista Brasileira De Hematologia E Hemoterapia</i> , 2017, 39, 57-59.	0.7	1
24	The treatment of CML at an environment with limited resources. <i>Hematology</i> , 2016, 21, 576-582.	1.5	11
25	Combination of low-dose imatinib plus nilotinib for the treatment of chronic-phase chronic myeloid leukaemia after imatinib failure. <i>Hematology</i> , 2016, 21, 411-414.	1.5	6
26	More about low-dose rituximab and plasma exchange as front-line therapy for patients with thrombotic thrombocytopenic purpura. <i>Hematology</i> , 2016, 21, 311-316.	1.5	27
27	Long-Term Insulin Independence in Type 1 Diabetes Mellitus Using a Simplified Autologous Stem Cell Transplant. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2141-2148.	3.6	24
28	Impact of outpatient non-myeloablative haematopoietic stem cell transplantation in quality of life vs. conventional therapy. <i>Psychology, Health and Medicine</i> , 2016, 21, 10-19.	2.4	8
29	Effective collection of peripheral blood stem cells in children weighing 20 kilogram or less in a single large-volume apheresis procedure. <i>Journal of Clinical Apheresis</i> , 2015, 30, 281-287.	1.3	22
30	Safety and Cost-Effectiveness of a Simplified Method for Lumbar Puncture in Patients with Hematologic Malignancies. <i>Acta Haematologica</i> , 2015, 133, 168-171.	1.4	5
31	Efficacy of mitoxantrone as frontline anthracycline during induction therapy in adults with newly diagnosed acute lymphoblastic leukemia: a single-center experience. <i>Leukemia and Lymphoma</i> , 2015, 56, 2524-2528.	1.3	3
32	Cost Structure and Clinical Outcome of a Stem Cell Transplantation Program in a Developing Country: The Experience in Northeast Mexico. <i>Oncologist</i> , 2015, 20, 386-392.	3.7	48
33	Cultural factors related to adherence to imatinib in CML: A Mexican perspective. <i>Hematology</i> , 2015, 20, 72-76.	1.5	7
34	Is There Still a Role for Low-Dose All-Transretinoic Acid in the Treatment of Acute Promyelocytic Leukemia in the Arsenic Trioxide Era?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2015, 15, 816-819.	0.4	2
35	Feasibility of an outpatient HLA haploidentical stem cell transplantation program in children using a reduced-intensity conditioning regimen and CD34 ⁺ CD19 ⁻ depletion. <i>Hematology</i> , 2014, 19, 10-17.	1.5	4
36	Allogeneic peripheral blood stem cell transplantation using reduced-intensity conditioning in an outpatient setting in ABO-incompatible patients: are survival and graft-versus-host disease different?. <i>Transfusion</i> , 2014, 54, 1269-1277.	1.6	15

#	ARTICLE	IF	CITATIONS
37	Characteristics and Clinical Evolution of Patients with Acute Myeloblastic Leukemia in Northeast Mexico: An Eight-Year Experience at a University Hospital. <i>Acta Haematologica</i> , 2014, 132, 144-151.	1.4	13
38	Chemotherapy Alone or HSCT After Reduced-Intensity Conditioning for Patients with Malignant Hematologic Diseases Are Not Associated to Metabolic Syndrome: A Cross-Sectional Observational Study. <i>Nutrition and Cancer</i> , 2014, 66, 924-929.	2.0	0
39	Safety and tolerability of intrathecal delivery of autologous bone marrow nucleated cells in children with cerebral palsy: an open-label phase I trial. <i>Cytotherapy</i> , 2014, 16, 810-820.	0.7	43
40	Eltrombopag and high-dose dexamethasone as frontline treatment of newly diagnosed immune thrombocytopenia in adults. <i>Blood</i> , 2014, 123, 3906-3908.	1.4	66
41	Obesity is associated with higher overall survival in patients undergoing an outpatient reduced-intensity conditioning hematopoietic stem cell transplant. <i>Blood Cells, Molecules, and Diseases</i> , 2013, 51, 61-65.	1.4	26
42	High response rate to low-dose rituximab plus high-dose dexamethasone as frontline therapy in adult patients with primary immune thrombocytopenia. <i>European Journal of Haematology</i> , 2013, 90, 494-500.	2.2	46
43	Higher doses of CD34+ progenitors are associated with improved overall survival without increasing GVHD in reduced intensity conditioning allogeneic transplant recipients with clinically advanced disease. <i>Journal of Clinical Apheresis</i> , 2013, 28, 349-355.	1.3	29
44	Low-dose rituximab for the treatment of acute thrombotic thrombocytopenic purpura: Report of four cases. <i>Hematology</i> , 2013, 18, 233-236.	1.5	20
45	Lower than expected cytogenetic and molecular response to imatinib in Mexican patients with chronic myelogenous leukemia. <i>Hematology</i> , 2013, 18, 224-229.	1.5	3
46	More about Imatinib and Nilotinib Combination Therapy in Chronic Myeloid Leukemia. <i>Acta Haematologica</i> , 2013, 129, 18-19.	1.4	5
47	Is there a benefit to adding rituximab to CHOP in the overall survival of patients with B-cell non-Hodgkin's lymphoma in a developing country?. <i>Hematology</i> , 2012, 17, 193-197.	1.5	6
48	Effectiveness of subcutaneous low-dose alemtuzumab and rituximab combination therapy for steroid-resistant chronic graft-versus-host disease. <i>Haematologica</i> , 2012, 97, 717-722.	3.5	22
49	Low incidence and severity of graft-versus-host disease after outpatient allogeneic peripheral blood stem cell transplantation employing a reduced-intensity conditioning. <i>European Journal of Haematology</i> , 2011, 87, 521-530.	2.2	13
50	Danazol as first-line therapy for aplastic anemia. <i>Annals of Hematology</i> , 2011, 90, 523-527.	1.8	59
51	Low-dose rituximab and alemtuzumab combination therapy for patients with steroid-refractory autoimmune cytopenias. <i>Blood</i> , 2010, 116, 4783-4785.	1.4	67
52	Outpatient reduced-intensity allogeneic stem cell transplantation for patients with refractory or relapsed lymphomas compared with autologous stem cell transplantation using a simplified method. <i>Annals of Hematology</i> , 2010, 89, 1045-1052.	1.8	10
53	Mobilization kinetics of CD133+ hematoprogenitor cells for hematopoietic grafting. <i>Transfusion</i> , 2009, 49, 532-535.	1.6	4
54	Therapeutic choices in patients with Ph-positive CML living in Mexico in the tyrosine kinase inhibitor era: SCT or TKIs?. <i>Bone Marrow Transplantation</i> , 2008, 42, 23-28.	2.4	47

#	ARTICLE	IF	CITATIONS
55	Outpatient allografting using non-myeloablative conditioning: the Mexican experience. Bone Marrow Transplantation, 2007, 40, 119-123.	2.4	24
56	Non-myeloablative stem cell transplantation in patients with relapsed acute lymphoblastic leukemia: results of a multicenter study. Bone Marrow Transplantation, 2007, 40, 535-539.	2.4	29
57	Successful father-to-son stem cell transplantation in a child with hemophagocytic lymphohistiocytosis using a reduced-intensity conditioning regimen. European Journal of Haematology, 2006, 77, 341-344.	2.2	2
58	Allografting in patients with severe, refractory aplastic anemia using peripheral blood stem cells and a fludarabine-based conditioning regimen: The Mexican experience. American Journal of Hematology, 2006, 81, 157-161.	4.1	42
59	Extramedullary Leukemic Relapses following Hematopoietic Stem Cell Transplantation with Nonmyeloablative Conditioning. International Journal of Hematology, 2005, 82, 262-265.	1.6	14
60	Platelet aggregation in children with acute lymphoblastic leukemia during induction of remission therapy. Archives of Medical Research, 2004, 35, 141-144.	3.3	9
61	Allogeneic Hematopoietic Stem Cell Transplantation with Non-Myeloablative Conditioning in Patients with Acute Myelogenous Leukemia Eligible for Conventional Allografting: A Prospective Study. Leukemia and Lymphoma, 2004, 45, 1191-1195.	1.3	28
62	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biology of Blood and Marrow Transplantation, 2003, 9, 157-161.	2.0	51
63	Reduced-intensity stem cell transplantation in children and adolescents: The Mexican experience. Biology of Blood and Marrow Transplantation, 2003, 9, 157-161.	2.0	41
64	Results of an allogeneic non-myeloablative stem cell transplantation program in patients with chronic myelogenous leukemia. Haematologica, 2002, 87, 894-6.	3.5	22